What if: A sliding scale were used to reimburse generic drugs to effectively drive down prices?

Uploaded on


  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Aidan Hollis University of Calgary July 2011
  • 2. Generic drug pricing in Canada
    • Ontario sets the price: basically the rule is that the maximum reimbursable price is a fixed fraction of the reference brand price.
    • Ontario first fixed the generic maximum at 75%, then 50%, and now it is moving towards 25%.
    • This is completely arbitrary: too low for some drugs and too high for others.
  • 3. Background
    • Ordinary competition doesn’t work well in generic drug markets in Canada
    • Insured consumers don’t hunt for low prices, so pharmacies exercise market power, and price up to the allowed ceiling
    • Competitive manufacturers sell at net prices far below the reimbursable price, since they compete to get their product stocked by the pharmacy.
  • 4. Net result
    • There is aggressive competition in many generic drug markets, but this isn’t resulting in low retail prices
    • Pharmacies are capturing large margins
    • We need a solution that preserves competition, but that also generates low prices.
  • 5. Descending royalty
    • The price would be determined by the number of entrants
    • Eg: If 1 generic, price is 50% of brand
    • If 2 generics, 35%
    • If 3 generics, 30%
    • If 4 generics, 25%
    • If 5 generics, 20%
    • If 6 generics, 15%
    • If 7 or more, 10% …
  • 6. Efficient pricing
    • Firms will enter as long as the price is above their cost
      • This system drives price towards marginal cost, just like regular competition
    • The first entrant gets rewarded with higher prices (at least temporarily)
    • The system eliminates the need for discretion by drug plan managers when claimed costs exceed 25% of the brand price.
    • Potentially very large savings on some drugs.
  • 7. Feasible and easy to try
    • Feasible: Ontario had a system for several years in which price was 70% if one generic; and 63% if two or more generics.
      • This system merely extends that.
    • Easy to try: The proposal can be assessed on one or two drugs, and then expanded if successful.
      • Best if provinces collaborate, since otherwise provincial policies that require drug manufacturers to offer them the lowest price in the country (like in Quebec, Manitoba and NFD) will undermine the approach.
  • 8. Financial impact: some examples Brand Generic ON ON Amlodipine 10mg 2.01 0.50 Venlafaxine hcl 75mg 1.76 0.44 Ramipril 10mg 1.01 0.25 Furosemide 40mg 0.13 0.06
  • 9. 25% of the brand price is not the cost of supply! The effect on roughly $5bn a year in generic spending could be large. Brand Generic ON ON FSS Amlodipine 10mg 2.01 0.50 0.02 Venlafaxine 75mg 1.76 0.44 0.19 Ramipril 10mg 1.01 0.25 0.06 Furosemide 40mg 0.13 0.06 0.02
  • 10. Thanks!
    • For more information see
    • http://bitly.com/genericprice